Figure 10.

Akt and GSK-3β phosphorylation in inotodiol-treated BMDCs. (A) BMDCs (2 × 10⁶) were treated with DMSO (0.01%) (None), inotodiol (25 µM), or LPS (1 µg/ml) for the indicated periods. The samples were then subjected to western blot analysis using anti-phosphorylated antibodies. β-Actin was used as loading control. (B) BMDCs (2 × 10⁶) were pretreated with (+Wortmannin) or not (−Wortmannin) with wortmannin (100 nM) for 10 min and then stimulated with DMSO (0.01%) (None), inotodiol (25 µM), or LPS (1 µg/ml) for 20 min. Samples were subjected to Western blot analysis, as in panel (A). Data represent four independent experiments.